China Grand Pharmaceutical and Healthcare Holdings Limited

Grand Journey for A Healthier World

GP (HK) Announces Positive Profit Alert

The Expected Increase in Consolidated Net Profit Attributable to Owners of the Company for FY2020 No Less Than 40%

READ MORE

Statement on Recent Fraudulent Use of the Commercial Name of GP (HK) to Conduct Internet Financial Fraud

READ MORE

GP (HK) Announces 2020 Annual Results Profit Attributable to Owners of the Company Significantly Increase 55.8% to HK$1,792.7 million Technological Innovation Drives the Internationalization Planning Multiple Material Investment and M&A Projects Proceed Steadily

GP (HK) Announces 2020 Annual Results Profit Attributable to Owners of the Company Significantly Increase 55.8% to HK$1,792.7 million Technological Innovation Drives the Internationalization Planning Multiple Material Investment and M&A Projects Proceed Steadily

READ MORE

SIR-Spheres® Y-90 Resin Microspheres Obtains Recommendation from NICE and Approval from the FDA to Conduct Clinical Trials on Primary Liver Cancer

SIR-Spheres® Y-90 Resin Microspheres Obtains Recommendation from NICE and Approval from the FDA to Conduct Clinical Trials on Primary Liver Cancer

READ MORE

GP (HK)’s Independently Developed Innovative Glaucoma Treatment Drug Obtained Drug Registration Certificate Breaking Through the Blue Ocean of The Ophthalmic Market Segment and Consolidating its Leading Position in Ophthalmic Drugs

GP (HK)’s Independently Developed Innovative Glaucoma Treatment Drug Obtained Drug Registration Certificate Breaking Through the Blue Ocean of The Ophthalmic Market Segment and Consolidating its Leading Position in Ophthalmic Drugs

READ MORE

GP (HK)’s First-In-Class Drug STC3141 for Sepsis has been Granted A “Notice of Approval for Clinical Trial of Drugs” Issued by the NMPA and Approved to Carry out Phase Ib Clinical Trial on ARDS Highlights its Ability to Implement the Commercialization of R&D Results

GP (HK)’s First-In-Class Drug STC3141 for Sepsis has been Granted A “Notice of Approval for Clinical Trial of Drugs” Issued by the NMPA and Approved to Carry out Phase Ib Clinical Trial on ARDS Highlights its Ability to Implement the Commercialization of R&D Results

READ MORE

READ MORE

Popular News

27 Mar

GP (HK)’s World-wide Innovative Drug STC3141 Got Approval for Phase II Clinical Research on COVID-19 ARDS and Phase IB Clinical Research on Sepsis, High-quality Product Contributes to Global Epidemic Prevention & Control

READ MORE

27 Mar

GP (HK) Enters into an Investment Agreement with eTheRNA Introducing the mRNA Vaccine Platform To Enrich Product Pipeline and Extend the Reach in Multiple Therapeutic Areas

READ MORE

27 Mar

GP (HK) Announces 2019 Annual Results

READ MORE

27 Mar

Yuanda medicine gets sepsis innovative medicine again

READ MORE

27 Mar

GP (HK) Obtains Medical Device Registration Certificate for the First Drug Coated Balloon Specified for Vascular Access for Hemodialysis in the PRC Market

READ MORE

27 Mar

GP (HK) Announces 2019 Annual Report Three Core Competitiveness Strengthens its Path to an International Pharm Company

READ MORE

27 Mar

GP (HK) Enters into an Investment Agreement with Revolmmune Introducing the World-Wide Innovative VSV-GPM To Strengthen the Strategic Planning in Tumor Precision Treatment and Tumor Immunotherapy

READ MORE

27 Mar

GP (HK) Announces 2020 Interim Results Profit Attributable to Owners of the Company Rapidly Increases 31.4% to HK$718.5 million With A Focus on Global Expansion and Self-Development Seven Investment, M&A and Cooperation Projects Progress Steadily

READ MORE

Media Report

Yuanda medicine gets sepsis innovative medicine again

Shanghai Securities News China Securities Network2020-3-27